Acute liver injury after SARS-CoV-2 vaccination and luspatercept administration in a patient with β-thalassemia

Ann Hematol. 2024 Mar;103(3):1025-1026. doi: 10.1007/s00277-023-05591-x. Epub 2024 Jan 3.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Activin Receptors, Type II* / therapeutic use
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Humans
  • Immunoglobulin Fc Fragments* / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Vaccination
  • beta-Thalassemia* / complications
  • beta-Thalassemia* / drug therapy

Substances

  • Activin Receptors, Type II
  • COVID-19 Vaccines
  • Immunoglobulin Fc Fragments
  • luspatercept
  • Recombinant Fusion Proteins